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Editorial on the Research Topic
Molecular Diagnostics in the Detection of Neurodegenerative Disorders
Neurodegenerative disorders encompass a range of medical conditions which primarily affect
the neurons in the human brains. Such conditions result in the disorders of the central nervous
system which eventually lead to the progressive loss of neural tissues including death of neurons
(Agrawal and Biswas, 2015). An impressive volume of research has been conducted over the last few
decades to advance our understanding of this fatal disease. The challenge to treat neurodegenerative
disorders lies in the inability of the neurons to regenerate on their own once they start functioning
abnormally after the neural deterioration or once a severe damage occurs to a neural tissue.
However, stem cell therapy has been proven to be potentially useful in neuroregeneration or even
neuronal cell replacement (Chung et al., 2002; Rachakonda et al., 2004). One of the most important
missions of diagnosis and prognosis of neurodegeneration is the ability of early detection of the
onset of neurodegeneration. An early diagnosis of the disease is critical as it provides a chance for an
early treatment that may be helpful to prevent further progression of the deadly neurodegeneration
and its aftermaths that takes millions of lives every year globally (Miller and O’Callaghan, 2015).
With an aim to provide a discussion platform to neurologists, neuroscientists and pathologists
for sharing the latest findings and knowledge on neurodegeneration and the molecular diagnostics
to detect and combat neurodegeneration, we have launched this special research topic onmolecular
diagnostics in the detection of neurodegenerative disorders. We anticipate that molecular
diagnostics will play an imperative role in near future for providing an effective diagnostic
solution to the complex problem of neurodegenerative diseases. Based on the available research
data, we firmly believe that molecular diagnostics can be effective to detect and diagnose
various neurological diseases such as Amyotrophic lateral sclerosis, Huntington’s, Alzheimer’s, and
Parkinson’s disease, at an early stage (Gasser et al., 2001a,b, 2003; Agrawal and Biswas, 2015).
Molecular diagnostics in neurodegenerative disorder is an emergent area of study, research and
development. It represents a multidisciplinary research field that offers plenty of opportunities
for collaboration between neurologists, psychologists, biologist and biomaterials scientists and
other trained personnel with the necessary experience in managing the diseases. We expect that
further developments in various molecular diagnostics will pave the way for the early detection of
neurodegeneration and effective treatment.
This e-book showcases important and significant reports that cover a wide range of areas
in neurodegeneration research and treatment. These include diagnosis and prognosis; role of
neuroactive drugs in regulating central nervous system; advances in novel biomarkers; brain injury
induced neurobehavioral outcomes and also connectivity between spinal muscular atrophy and
loss of α-motors neurons among other reports. One of the reports investigates the origin and
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potential function of corpora amylacea (CA) which are found in
large numbers in the central nervous system of the patients with
neurodegenerative diseases. Immunohistochemistry analyses
were employed to reveal fungal proteins present in CA from
patients diagnosed with Alzheimer’s disease (Pisa et al.). An
insight into the prospective roles of haptoglobin (Hp) (an
endogenous hemoglobin-binding protein) in traumatic brain
injury and other acute brain injuries is discussed in another
report which portrays to be helpful in understanding the
inconsistency in outcomes of clinical studies regarding the
importance of Hp phenotypes in such brain injuries (Glushakov
et al.). This study is a step forward to develop and progress with
new therapeutics in the prevention of cerebral hemorrhage which
is a common feature of traumatic brain injury and its associated
chronic disabilities (Glushakov et al.). Furthermore, important
and significant biomarkers for neurodegeneration have been
investigated and studied for their sensitivity and specificity in this
e-book that sheds new lights in treatment of irreversible cognitive
deficit and dementia in elderly population. Biomarkers represent
important molecular diagnostic tools and thus the development
of novel biomarkers could bring significant breakthroughs in an
early diagnosis of neurodegeneration (Sfera et al.).
In a particular review, the application of stem cells and
induced pluripotent stem cells in combating neurodegeneration
is discussed that addresses the issues of diagnosis, modeling,
and therapeutic transplantation strategies (Singh et al.). In
another review, adropin is discussed as a biomarker for the
diagnosis of central nervous system disorders and is considered
as a potential therapeutic candidate in central nervous system
injuries (Shahjouei et al.). It is believed that hyper excitability
in neuronal network possibly contributes to the cognitive
deficits in Alzheimer’s disease and this is addressed in a
research report that sheds light on the mechanism of aberrant
neuronal networks in Alzheimer’s disease (Wang et al.). To this
end, researchers conducted investigations on the excitability in
cultured pyramidal neurons from APP/PS1 mice using patch
clamp recording techniques. This provides an important insight
into the pathogenesis of Alzheimer’s disease that could be helpful
in developing new therapeutic avenues in the future (Wang et al.).
This e-book covers another area of neurodegeneration: spinal
muscular atrophy, which is an early-onset, autosomal recessive
neurodegenerative disease that is characterized by the loss of
spinal α-motor neurons leading to infant deaths (Butchbach).
The author highlights why a better understanding of the
underlying mechanism causing spinal muscular atrophy and
the accurate measurements thereof are crucial to control such
neurodegenerative disease in infants (Butchbach). The molecular
mechanisms of C9orf72 gene causing amyotrophic lateral
sclerosis, frontotemporal dementias and atypical parkinsonian
syndromes are also discussed (Munteanu and Lynch).
In concluding our thoughts and deliberations, we do
hope that this discussion forum in the form of an edited
e-book will advance our further understanding to have an
enhanced insight of neurogenesis and eventual cure for
neurodegenerative diseases. Future research directions might
involve multifunctional biomolecular diagnostic markers and
technology platforms that would significantly enhance and
augment the accuracy, specificity and sensitivity that would drive
an early diagnosis and prognosis of various neurodegenerative
disorders.
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